Medicine and Health Sciences Commons^™

Ephb-Ephrinb Cis Interaction Regulates Filopodial Movement, Yu-Ting Mao, Matthew B. Dalva

Department of Neuroscience Posters

Neural connections are initiated by motile dendritic and axonal protrusions, such as dendritic filopodia and axonal growth cones. Dendritic filopodia interview many axons and then choose the correct ones to make stable contacts. Specific rates of EphB activation in dendritic filopodia controls the decision of filopodia to reject or stabilize a synaptic contact onto an axon. However, it remains unknown how EphB activity in dendritic filopodia is modulated to regulate filopodial decisions. Here using an optogenetic approach, we find that photoactivation of a cis-interaction between EphB2 and ephrinB3 prevents filopodial retraction, likely driving filopodial stabilization. Using photoactivatable EphB2KD as a …

Role Of Ribosome Recycling Factor As A Ribosome Releasing Factor, Yoshio Inokuchi, Fabio Quaglia, Akikazu Hirashima, Yoshihiro Yamamoto, Hideko Kaji, A. Kaji

Department of Biochemistry and Molecular Biology Posters

The objective of this presentation is to study the in vivo actions of ribosome recycling factor (RRF) and compare them with those found in vitro. RRF is known to catalyze three separate reactions: release of tRNA and mRNA from the post-termination complex (PoTC), and splitting of the ribosome of the PoTC. To study the mechanism of RRF reaction in vivo, we used E. coli harboring temperature sensitive (ts) RRF and assayed by following downstream reading of translationally coupled ORF. At the non-permissive temperature, ribosomes remain on the termination codon of the junction sequence of coupled ORFs and translate downstream ORF …

Apixaban Discontinuation Prior To Major Surgery: Results From A Prospective Single Center Study, Edwin Lam, Luis Eraso, Taki Galanis, Walter K. Kraft, Geoffrey Ouma, Lynda Thomson, Eugene Viscusi, Douglas Stickle, Jerald Z. Gong, Suzanne Adams, Geno Merli

Department of Pharmacology and Experimental Therapeutics Posters

Primary Objective

• Estimate the proportion of patients who achieve a plasma apixaban concentration of/mL following at least 48 hours of discontinuation prior to surgery or invasive procedure

Secondary Objective

• Perioperative and follow up arterial or venous thromboembolic events, major bleeding, clinically significant non-major bleeding complications. Correlation of apixaban anti-Factor Xa (FXa) activity and plasma apixaban concentrations at pre-admission and prior to surgery